Initial treatment choice in depression: Impact on medical expenditures

PharmacoEconomics

Volumn 17, Issue 4, 2000, Pages 371-382

  Edgell, Eric T ^a   Hylan, Timothy R ^b   Draugalis, JoLaine R ^c   Coons, Stephen Joel ^c  

^a ELI LILLY AND COMPANY   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ARTICLE; CONTROLLED STUDY; DEPRESSION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY;

EID: 0034056698     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017040-00007     Document Type: Article

References (37)

1. 1. Myers JK, Weissman MM, Tischler GL, et al. Six-month prevalence of psychiatric disorders in three communities. Arch Gen Psychiatry 1984; 41: 959-67
2. 2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19
3. 3. Klerman GL, Weissman MM. Increasing rates of depression. JAMA 1989; 261: 2229-35
4. 4. Cross-National Collaborative Group. The changing rate of major depression: cross-national comparisons. JAMA 1992; 268: 3098-105
5. 5. Stoudemire A, Frank R, Hedemark N, et al. The economic burden of depression. Gen Hosp Psychiatry 1986; 8: 387-94
6. 6. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405-18
7. 7. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16: 715-30
8. 8. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995; 23: 395-412
9. 9. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs. tricyclic antidepressants. JAMA 1996; 275: 1897-902
10. 10. Thompson D, Buesching D. Gregor KJ, et al. Patterns of antidepressant use and their relation to costs of care. Am J Managed Care 1996; 2: 1239-46
11. 11. Hylan TR, Crown WH, Meneades L, et al. SSRI and TCA antidepressant selection and health care costs: a multivariate analyses. J Affect Disord 1998; 47: 71-9
12. 12. Hylan TR, Neslun CA, Baldridge RM, et al. SSRI selection and anxiolytic and sedative-hypnotic prescribing: a multivariate analyses. J Clin Outcomes Manage 1997; 4: 16-22
13. 13. Revicki DA, Brown RE, Keller MB, et al. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1997; 58: 47-58
14. 14. Skaer TL, Sclar DA, Robison LM, et al. Antidepressant pharmacotherapy: effect on women's resource utilisation within a health maintenance organization. Appl Ther 1996; 1: 45-52
15. 15. Boyer WF, Feighner JP. The financial implication of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients. In: Jonsson B, Rosenbaum J, editors. Health economics of depression. Chichester: Wiley, 1993
16. 16. Hatziandreu EJ, Brown RE, Revicki DA, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics 1994; 5: 249-64
17. 17. Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatr Serv 1997; 48: 1420-6
18. 18. Sturm R, Wells KB. How can care for depression become more cost-effective? JAMA 1995; 273: 51-8
19. 19. Von Korff M, Ormel J, Katon W, et al. Disability and depression among high utilizers of health care: a longitudinal analysis. Arch Gen Psychiatry 1992; 49: 91-100
20. 20. Levinson JL, Hammer RM, Rossiter LF. Relation of psychopathology in general medical inpatients to use and cost of services. Am J Psychiatry 1990; 147: 1498-503
21. 21. Verbosky LA, Franco K, Zrull JP. The relationship between depression and length of stay in the general hospital patient. J Clin Psychiatry 1993; 54: 177-81
22. 22. Simon G, Ormel J, VonKorff M, et al. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995; 152: 352-7
23. 23. Henk HJ, Katzelnick DJ, Kohak KA, et al. Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch Gen Psychiatry 1996; 53: 899-904
24. 24. Depression Guideline Panel. Depression in primary care: vol. 2. Treatment of major depression. AHCPR publication no. 93-0551. Clinical practice guideline no. 5. Rockville (MD): US Department of Health and Human Services, US Public Health Service, Agency for Health Care Policy and Research, 1993
25. 25. American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993; 150 Suppl.: 1-26
26. 26. Hornbrook M, Hurtado AV, Johnson R. Health care episodes: definition, measurement and use. Med Care Rev 1985; 42: 163-219
27. 27. Lee LF. Generalized econometric models with selectivity. Econometrica 1983; 51: 507-12
28. 28. Crown WH, Obenchain RL, Englehart L, et al. The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. Stat Med 1998; 17: 1943-58
29. 29. Heckman JJ. Sample bias as a specification error. Econometrica 1979; 47: 153-62
30. 30. Coulson N, Edward SB, Neslusan C. Estimating the moral hazard effect of supplemental medical insurance in the demand for prescription drug use in the elderly Am Econ Rev 1995; 85: 122-6
31. 31. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45 (2): 197-203
32. 32. SAS Institute, Inc. SAS/STAT user's guide: vol. 1 and 2. 4th ed, 6th version. Cary (NC): SAS Institute, Inc., 1990
33. 33. Greene WH. LIMDEP Version 7.0. Bellport (NY): Econometric Software, Inc., 1995
34. 34. Wells KB, Katon W, Rogers WH, et al. Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the Medical Outcomes Study. Am J Psychiatry 1994; 151: 694-700
35. 35. Regier DA, Hirschfeld RM, Goodwin FK, et al. The NIMH Depression Awareness, Recognition, and Treatment Program: structure, aims, and scientific basis. Am J Psychiatry 1988; 145: 1351-7
36. 36. Goldberg D, Huxley P. Mental illness in the community: the pathway to psychiatric care. London: Tavistock, 1980
37. 37. Freeling P, Rao BM, Paykel ES, et al. Unrecognized depression in general practice. BMJ 1985; 290: 1880-3